不同性别血浆来源的静注人免疫球蛋白的自身抗体谱差异性研究*

doi:10.3969/j.issn.1671-2587.2025.01.013

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (1): 89-100.DOI: 10.3969/j.issn.1671-2587.2025.01.013

不同性别血浆来源的静注人免疫球蛋白的自身抗体谱差异性研究^*

张巍¹, 黄耀敬², 马莉¹, 张运佳³, 侯明霞³, 张战³, 王宗奎¹, 李长清¹

¹中国医学科学院输血研究所,四川成都 610052;
²巴马莱士单采血浆站,广西河池 547500;
³深圳市卫光生物制品股份有限公司,广东深圳 518107

收稿日期:2024-07-16 发布日期:2025-02-25
通讯作者: 李长清,主要从事血液安全、血液制品的疗效机制等方面的研究,（E-mail）lichangqing268@163.com。共同通信作者：王宗奎,主要从事血液制品研发、血液制品的疗效机制等方面的研究,（E-mail）zongkui.wang@ibt.pumc.edu.cn。
作者简介:张巍,主要从事IVIG在自身免疫病中的作用及机制研究,（E-mail）18581556966@163.com。并列第一作者：黄耀敬,主要从事血液制品原料血浆方面的研究,（E-mail）huangyaojing@sina.com。
基金资助:
*本课题受四川省科技厅项目（No.2023ZYD0085,2023NSFSC0714,2023ZHCG0066）、四川省医学会课题（No.Q22009）资助

Sex-specific Variations in the Autoantibody Profiles of Intravenous Human Immunoglobulins Derived from Plasma Donations

ZHANG Wei¹, HUANG Yaojing², MA Li¹, ZHANG Yunjia³, Hou Mingxia³, ZHANG Zhan³, WANG Zongkui¹, LI Changqing¹

¹Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052;
²Bama Plasmapheresis Center, Hechi 547500; 3Shenzhen Weiguang Biological Products Co., Ltd., Shenzhen 518107

Received:2024-07-16 Published:2025-02-25

摘要/Abstract

摘要： 目的明确不同性别血浆来源的静注人免疫球蛋白（intravenous immunoglobulin sourced from distinct sex-specific plasma,DSP-IVIG)的自身抗体谱差异。方法使用HuProt^TM20K芯片检测三种DSP-IVIG的自身抗体谱,对差异表达的自身抗体蛋白进行生物信息学分析。结果三种DSP-IVIG的抗自身蛋白抗体种类存在差异。这些差异蛋白主要参与：T细胞系的分化、IL-17信号通路、细胞因子、趋化因子等构成的免疫调控网络。结论三种DSP-IVIG中的抗自身蛋白抗体种类存在差异。

关键词: 静注人免疫球蛋白, 不同性别血浆来源的静注人免疫球蛋白, 自身抗体谱, 自身免疫病

Abstract: Objective To investigate the differences in autoantibody profiles of intravenous immunoglobulin (IVIG) derived from distinct sex-specific plasma (DSP-IVIG). Methods To achieve this objective, we used the HuProt^TM20K arrays, a comprehensive platform for autoantibody detection, to analyze the autoantibody profiles of DSP-IVIG. Then, we did a bioinformatics analysis to characterize the differentially expressed autoantibody proteins. Results There were significant differences in the autoantibody profiles between DSP-IVIG samples. These differences mainly involved the immune regulatory network encompassing critical processes such as T cell line differentiation, IL-17 signaling pathway modulation, and the interplay of cytokines and chemokines. Conclusion Notable sex-specific variations exist in the autoantibody profiles of IVIG derived from plasma of different sexes.

Key words: Intravenous Immunoglobulin, IVIG derived from distinct sex-specific plasma, Autoantibody profiles, Autoimmune diseases

中图分类号:

R457

张巍, 黄耀敬, 马莉, 张运佳, 侯明霞, 张战, 王宗奎, 李长清. 不同性别血浆来源的静注人免疫球蛋白的自身抗体谱差异性研究^*[J]. 临床输血与检验, 2025, 27(1): 89-100.

ZHANG Wei, HUANG Yaojing, MA Li, ZHANG Yunjia, Hou Mingxia, ZHANG Zhan, WANG Zongkui, LI Changqing. Sex-specific Variations in the Autoantibody Profiles of Intravenous Human Immunoglobulins Derived from Plasma Donations[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 89-100.

参考文献

[1] MATZDORFF A,MEYER O,OSTERMANN H,et al.Immune thrombocytopenia-current diagnostics and therapy:recommendations of a joint working group of DGHO,ÖGHO,SGH,GPOH,and DGTI[J].Oncol Res Treat,2018,41(Suppl 5):1-30.
[2] SALAMA A.Emerging drugs for immune thrombocytopenia(ITP)[J].Expert Opin Emerg Drugs,2017,22(1):27-38.
[3] RODEGHIERO F,STASI R,GERNSHEIMER T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic Purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386-2393.
[4] KAPUR R,EINARSDOTTIR H K,VIDARSSON G.IgG-effector functions:“the good,the bad and the ugly”[J].Immunol Lett,2014,160(2):139-144.
[5] MA L,ZHANG W,HOU M X,et al.Analysis of sialic acid levels in Chinese intravenous immunoglobulins by high-performance liquid chromatography with fluorescence detection[J].Biomed Chromatogr,2019,33(4):e4452.
[6] AUDIA S,BONNOTTE B.Emerging therapies in immune thrombocytopenia[J].J Clin Med,2021,10(5):1004.
[7] LEONTYEV D,KATSMAN Y,BRANCH D R.Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP[J].Blood,2012,119(22):5261-5264.
[8] SCHWAB I,MIHAI S,SEELING M,et al.Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo[J].Eur J Immunol,2014,44(5):1444-1453.
[9] SPYCHER M,MATOZAN K,MINNIG K,et al.In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations[J].Vox Sang,2009,97(4):348-354.
[10] WASSERMAN R L,GARCIA D,GREENER B N,et al.Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products,BIVIGAM® and ASCENIV™[J].Immunotherapy,2019,11(16):1423-1433.
[11] MIKOLAJCZYK M G,CONCEPCION N F,WANG T,et al.Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations[J].Clin Diagn Lab Immunol,2004,11(6):1158-1164.
[12] ORANGE J S,DU W,FALSEY A R.Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses[J].Front Immunol,2015,6:431.
[13] PETER J G,CHAPEL H.Immunoglobulin replacement therapy for primary immunodeficiencies[J].Immunotherapy,2014,6(7):853-869.
[14] TZEKOU A,FEHLINGS M G.Treatment of spinal cord injury with intravenous immunoglobulin G:preliminary evidence and future perspectives[J].J Clin Immunol,2014,34(Suppl 1):S132-S138.
[15] FRAUGER E,GRASSI J,PRADEL V,et al.Use of intravenous immunoglobulins in clinical practice:data from three French University hospitals[J].Fundam Clin Pharmacol,2011,25(6):753-761.
[16] EL-SHANAWANY T,JOLLES S.Intravenous immunoglobulin and autoimmune disease[J].Ann N Y Acad Sci,2007,1110:507-515.
[17] SILLIMAN C C,DZIECIATKOWSKA M,MOORE E E,et al.Proteomic analyses of human plasma:Venus versus Mars[J].Transfusion,2012,52(2):417-424.
[18] 谢勇,唐诗佳,王贺,等.四川省部分地区献血浆人群调查与分析[J].中国输血杂志,2015,28(3):307-308.
[19] SUN P,ZHANG W,DU X,et al.Demographic characteristics and lifestyle habits of Chinese plasma donors:a multicenter study[J].Med Sci Monit,2021,27:e931471.
[20] DESAI M K,BRINTON R D.Autoimmune disease in women:endocrine transition and risk across the lifespan[J].Front Endocrinol(Lausanne),2019,10:265.
[21] HU C J,SONG G,HUANG W,et al.Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays[J].Mol Cell Proteomics,2012,11(9):669-680.
[22] HU C J,HUANG W,CHEN H,et al.Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus[J].PLoS One,2015,10(5):e0126643.
[23] ZHANG W,YUAN X,WANG Z K,et al.Study on the treatment of ITP mice with IVIG sourced from distinct sex-special plasma(DSP-IVIG)[J].Int J Mol Sci,2023,24(21):15993.
[24] DUELLBERG C,HANNAPPEL A,KISTNER S,et al.Biochemical characterization of a new 10% IVIG preparation[IgG next generation(BT595)/yimmugo®]obtained from a manufacturing process preserving IgA/IgM potential of human plasma[J].Drugs R D,2023,23(3):245-255.
[25] Arumugham V B,Rayi A.Intravenous Immunoglobulin(IVIG)[J/OL].(2020-07-04).https://www.researchgate.net/publication/344176256_Intravenous_Immunoglobulin_IVIG_-_StatPearls_-_NCBI_Bookshelf.
[26] KLEIN S L,FLANAGAN K L.Sex differences in immune responses[J].Nat Rev Immunol,2016,16(10):626-638.
[27] ZHU Y,CAI X L,LIU Y,et al.Serum albumin,but not bilirubin,is associated with diabetic chronic vascular complications in a Chinese type 2 diabetic population[J].Sci Rep,2019,9(1):12086.
[28] LIU J,WANG Y,XIONG E M,et al.Role of the IgM fc receptor in immunity and tolerance[J].Front Immunol,2019,10:529.
[29] ZHANG R,SHUAI S P,ZHANG H X,et al.Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients[J].Ital J Pediatr,2023,49(1):78.
[30] TAN X H,ZHANG X W,WANG X Y,et al.A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing:a retrospective study on 5277 patients[J].Sci Rep,2019,9(1):1722.
[31] DENG L F,WANG T,DUAN Y,et al.Neutrophil percentage-to-albumin ratio is a potential marker of intravenous immunoglobulin resistance in Kawasaki disease[J].Sci Rep,2024,14(1):15232.
[32] GUPTA M,JOHANN-LIANG R,BUSSEL J B,et al.Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease[J].Cardiology,2002,97(4):180-182.
[33] WANG Y,CAO Y Y,LI Y,et al.Development of an immunoinflammatory indicator-related dynamic nomogram based on machine learning for the prediction of intravenous immunoglobulin-resistant Kawasaki disease patients[J].Int Immunopharmacol,2024,134:112194.
[34] WANG C X,CAO L,MEI W D,et al.The V-shaped curve relationship between fasting plasma glucose and human serum albumin in a large health checkup population in China[J].BMC Endocr Disord,2023,23(1):192.
[35] KHAN S R,VAN DER BURGH A C,PEETERS R P,et al.Determinants of serum immunoglobulin levels:a systematic review and meta-analysis[J].Front Immunol,2021,12:664526.
[36] RADOSEVICH M,BURNOUF T.Intravenous immunoglobulin G:trends in production methods,quality control and quality assurance[J].Vox Sang,2010,98(1):12-28.
[37] BARAHONA AFONSO A F,JOÃO C M P.The production processes and biological effects of intravenous immunoglobulin[J].Biomolecules,2016,6(1):15.
[38] SUN Y Y,LIU C X,ZHONG H D,et al.Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray[J].Acta Biochim Biophys Sin,2022,54(12):1909-1916.
[39] YANG Q,YE H,SUN G Y,et al.Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma[J].Mol Oncol,2023,17(5):887-900.
[40] DUNN S E,PERRY W A,KLEIN S L.Mechanisms and consequences of sex differences in immune responses[J].Nat Rev Nephrol,2024,20(1):37-55.
[41] DING B J,LIU L,DAI Y T,et al.Identification and verification of differentially expressed key genes in peripheral blood-derived T cells between chronic immune thrombocytopenia patients and healthy controls[J].Bioengineered,2022,13(5):13587-13595.
[42] CAO J J,ZHAN Y X,JI L L,et al.Proinflammatory plasticity towards Th17 paradigm of regulatory T cells consistent with elevated prevalence of TGFBR2 variants in elderly patients with primary immune thrombocytopenia[J].BMC Immunol,2023,24(1):6.
[43] LIU H Y,LIU X Y,ZHANG G Y,et al.The short-term predictive value of CD4+ cells for combination therapy with high-dose dexamethasone and immunoglobulin in newly diagnosed primary immune thrombocytopenia patients[J].Thromb Res,2022,218:157-168.
[44] LI Q Z,LIU Y,WANG X J,et al.Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia[J].Exp Biol Med(Maywood),2021,246(15):1688-1697.
[45] SEGÚ-VERGÉS C,CAÑO S,CALDERÓN-GÓMEZ E,et al.Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system[J].Front Immunol,2022,13:901872.
[46] 马亮亮,梁燕,方美云.糖皮质激素受体和热休克蛋白90与原发免疫性血小板减少症患者糖皮质激素抵抗关系的研究[J].中华血液学杂志,2012,33(9):733-737.
[47] RIPLEY B J M,ISENBERG D A,LATCHMAN D S.Elevated levels of the 90kDa heat shock protein(hsp90)in sle correlate with levels of IL-6 and autoantibodies to hsp90[J].J Autoimmun,2001,17(4):341-346.
[48] SAITO K,KUKITA K,KUTOMI G,et al.Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE[J].Eur J Immunol,2015,45(7):2028-2041.
[49] SHUKLA H D,PITHA P M.Role of hsp90 in systemic lupus erythematosus and its clinical relevance[J].Autoimmune Dis,2012,2012:728605.
[50] RODRIGUEZ E,GUEVARA J,PAEZ A,et al.The altered expression of inflammation-related molecules and secretion of IL-6 and IL-8 by HUVEC from newborns with maternal inactive systemic lupus erythematosus is modified by estrogens[J].Lupus,2008,17(12):1086-1095.
[51] HU S X,XU Q,XIAO W Z,et al.The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus[J].J Huazhong Univ Sci Technolog Med Sci,2006,26(6):664-666.
[52] HU C,YANG J,QI Z P,et al.Heat shock proteins:Biological functions,pathological roles,and therapeutic opportunities[J].MedComm,2022,3(3):e161.
[53] GE J,LIU Y.Heat shock protein-70 is elevated in childhood primary immune thrombocytopenia[J].Eur J Med Res,2022,27(1):244.
[54] JONES R J,SINGH R K,SHIRAZI F,et al.Intravenous immunoglobulin G suppresses heat shock protein(HSP)-70 expression and enhances the activity of HSP90 and proteasome inhibitors[J].Front Immunol,2020,11:1816.

不同性别血浆来源的静注人免疫球蛋白的自身抗体谱差异性研究^*

Sex-specific Variations in the Autoantibody Profiles of Intravenous Human Immunoglobulins Derived from Plasma Donations

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	孙杨, 牛佳萌, 邢莉莉, 马婷, 杜工亮, 李学文, 王亚琴, 王李秦, 陈萍, 王文华, 杨颖群, 宋奥微, 谢昕昕, 宋耀军, 王妙妮, 常婧妍, 田芬芳, 杨江存. 4 ℃冷藏保存血小板在外科出血患者的临床疗效观察：一项随机对照可行性研究^*[J]. 临床输血与检验, 2025, 27(2): 145-155.
[2]	付丽辉, 马春娅, 罗圆圆, 沈伟, 向东, 于洋. 一例意外抗体阳性患者造血干细胞移植后抗体监测结果分析[J]. 临床输血与检验, 2025, 27(2): 169-174.
[3]	王刚, 高旖鑫, 吴林燕, 杨明会, 何苏英, 彭永正. 半全血置换治疗低体重儿童自身免疫性溶血性贫血并发溶血危象1例[J]. 临床输血与检验, 2025, 27(2): 196-199.
[4]	李尚武, 康甜, 袁媛, 陈静, 罗佳. 中国无偿献血人群2013—2023年献血者归队合格率的Meta分析^*[J]. 临床输血与检验, 2025, 27(2): 217-223.
[5]	卿芸, 黄霞. G6PD缺乏症在输血医学中的研究进展[J]. 临床输血与检验, 2025, 27(2): 261-266.
[6]	李津杞, 钱宝华, 许硕贵, 顾海慧. 血浆拓展性应用及相关成分研究进展^*[J]. 临床输血与检验, 2025, 27(2): 267-273.
[7]	庄远, 于洋. 输血（医学）科基于离心分离技术建立单采/血液净化治疗体系的探索[J]. 临床输血与检验, 2024, 26(6): 721-725.
[8]	刘晓敏, 庄远, 于洋. 我国医疗机构输血科开展输血治疗的现状调查报告[J]. 临床输血与检验, 2024, 26(6): 740-743.
[9]	沈倩云, 程文国, 侯书宁, 姚根宏. ABO新生儿溶血病患儿血浆中血管细胞粘附分子-1的表达差异与意义^*[J]. 临床输血与检验, 2024, 26(6): 744-749.
[10]	王丹婷, 龙红惠, 牛迎迎, 黄春妍. 微柱凝胶法交叉配血次侧不合的原因探讨及临床意义分析[J]. 临床输血与检验, 2024, 26(6): 750-754.
[11]	车扬, 刘铮, 周小玉. 原发性肝癌肝切除患者术后不同种类血浆输注疗效的回顾性分析[J]. 临床输血与检验, 2024, 26(6): 755-761.
[12]	郑妍, 王文婷, 杨龙飞, 王琼, 穆士杰. 8例RhD变异型的血清学特征及基因序列分析[J]. 临床输血与检验, 2024, 26(6): 762-765.
[13]	梁春艳, 段莉, 刘友迎, 刘方久. 住院患者输血相关循环超负荷的危险因素及预测模型的构建与验证[J]. 临床输血与检验, 2024, 26(6): 771-776.
[14]	蔡茵, 陈至颖, 蒋苓, 任亚娜, 郑岚, 周国平. 上海地区无偿献血人群HLA抗体筛查分析[J]. 临床输血与检验, 2024, 26(6): 777-780.
[15]	郭瑞, 侯云, 苏常山, 钟建玲, 甄志军, 何燕琴, 鲍琳, 崔立晔, 孙俊艳, 张剑, 李浩, 王振兴, 张微, 李晶, 付恒, 蔡晓波, 卢然然, 沈有华, 王登峰, 胡官林, 刘洋, 邱艳. 采用发病率-窗口期模型分析2018—2022年国内21家采供血机构输血传播HBV检测残余风险^*[J]. 临床输血与检验, 2024, 26(6): 781-786.